103 related articles for article (PubMed ID: 15686898)
1. Molecular docking of the highly hypolipidemic agent alpha-asarone with the catalytic portion of HMG-CoA reductase.
Medina-Franco JL; López-Vallejo F; Rodríguez-Morales S; Castillo R; Chamorro G; Tamariz J
Bioorg Med Chem Lett; 2005 Feb; 15(4):989-94. PubMed ID: 15686898
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and docking of highly hypolipidemic agents: Schizosaccharomyces pombe as a new model for evaluating alpha-asarone-based HMG-CoA reductase inhibitors.
Argüelles N; Sánchez-Sandoval E; Mendieta A; Villa-Tanaca L; Garduño-Siciliano L; Jiménez F; Cruz Mdel C; Medina-Franco JL; Chamorro-Cevallos G; Tamariz J
Bioorg Med Chem; 2010 Jun; 18(12):4238-48. PubMed ID: 20576575
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and highly potent hypolipidemic activity of alpha-asarone- and fibrate-based 2-acyl and 2-alkyl phenols as HMG-CoA reductase inhibitors.
Mendieta A; Jiménez F; Garduño-Siciliano L; Mojica-Villegas A; Rosales-Acosta B; Villa-Tanaca L; Chamorro-Cevallos G; Medina-Franco JL; Meurice N; Gutiérrez RU; Montiel LE; Cruz Mdel C; Tamariz J
Bioorg Med Chem; 2014 Nov; 22(21):5871-82. PubMed ID: 25311563
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of HMG-CoA Reductase: Current and Future Prospects.
Singh N; Tamariz J; Chamorro G; Medina-Franco JL
Mini Rev Med Chem; 2009 Oct; 9(11):1272-83. PubMed ID: 19929805
[TBL] [Abstract][Full Text] [Related]
5. Structural mechanism for statin inhibition of HMG-CoA reductase.
Istvan ES; Deisenhofer J
Science; 2001 May; 292(5519):1160-4. PubMed ID: 11349148
[TBL] [Abstract][Full Text] [Related]
6. Insight into the mechanism of polyphenols on the activity of HMGR by molecular docking.
Islam B; Sharma C; Adem A; Aburawi E; Ojha S
Drug Des Devel Ther; 2015; 9():4943-51. PubMed ID: 26357462
[TBL] [Abstract][Full Text] [Related]
7. The structure of the catalytic portion of human HMG-CoA reductase.
Istvan ES; Deisenhofer J
Biochim Biophys Acta; 2000 Dec; 1529(1-3):9-18. PubMed ID: 11111074
[TBL] [Abstract][Full Text] [Related]
8. Natural Inhibitors of HMG-CoA Reductase-An Insilico Approach Through Molecular Docking and Simulation Studies.
Suganya S; Nandagopal B; Anbarasu A
J Cell Biochem; 2017 Jan; 118(1):52-57. PubMed ID: 27216569
[TBL] [Abstract][Full Text] [Related]
9. Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia.
da Silva VB; Taft CA; Silva CH
J Phys Chem A; 2008 Mar; 112(10):2007-11. PubMed ID: 18044855
[TBL] [Abstract][Full Text] [Related]
10. Proteopedia entry: HMG-CoA reductase.
Canner D
Biochem Mol Biol Educ; 2011; 39(1):64. PubMed ID: 21433257
[No Abstract] [Full Text] [Related]
11. Exploration of natural product ingredients as inhibitors of human HMG-CoA reductase through structure-based virtual screening.
Lin SH; Huang KJ; Weng CF; Shiuan D
Drug Des Devel Ther; 2015; 9():3313-24. PubMed ID: 26170618
[TBL] [Abstract][Full Text] [Related]
12. Discovery of new druggable sites in the anti-cholesterol target HMG-CoA reductase by computational alanine scanning mutagenesis.
Gesto DS; Cerqueira NM; Ramos MJ; Fernandes PA
J Mol Model; 2014 Apr; 20(4):2178. PubMed ID: 24671303
[TBL] [Abstract][Full Text] [Related]
13. Binding effect and design of a competitive inhibitory peptide for HMG-CoA reductase through modeling of an active peptide backbone.
Pak VV; Koo M; Kim MJ; Yun L; Kwon DY
Bioorg Med Chem; 2008 Feb; 16(3):1309-18. PubMed ID: 17977732
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis.
Istvan ES; Palnitkar M; Buchanan SK; Deisenhofer J
EMBO J; 2000 Mar; 19(5):819-30. PubMed ID: 10698924
[TBL] [Abstract][Full Text] [Related]
15. Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening.
Zhang QY; Wan J; Xu X; Yang GF; Ren YL; Liu JJ; Wang H; Guo Y
J Comb Chem; 2007; 9(1):131-8. PubMed ID: 17206841
[TBL] [Abstract][Full Text] [Related]
16. Exploration of virtual candidates for human HMG-CoA reductase inhibitors using pharmacophore modeling and molecular dynamics simulations.
Son M; Baek A; Sakkiah S; Park C; John S; Lee KW
PLoS One; 2013; 8(12):e83496. PubMed ID: 24386216
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in silico studies of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitory activity of the cowpea Gln-Asp-Phe peptide.
Silva MBCE; Souza CADC; Philadelpho BO; Cunha MMND; Batista FPR; Silva JRD; Druzian JI; Castilho MS; Cilli EM; Ferreira ES
Food Chem; 2018 Sep; 259():270-277. PubMed ID: 29680054
[TBL] [Abstract][Full Text] [Related]
18. 2,4,5-trimethoxycinnamic acid: the major metabolite of alpha-asarone, retains most of the pharmacological properties of alpha-asarone.
Antunez-Solis J; Hernández-Derramadero F; Aquino-Vega M; Ibarra-Ramírez S; Rodríguez-Páez L; Baeza I; Wong C
J Enzyme Inhib Med Chem; 2009 Jun; 24(3):903-9. PubMed ID: 18686138
[TBL] [Abstract][Full Text] [Related]
19. IAF, QGF, and QDF Peptides Exhibit Cholesterol-Lowering Activity through a Statin-like HMG-CoA Reductase Regulation Mechanism: In Silico and In Vitro Approach.
Silva M; Philadelpho B; Santos J; Souza V; Souza C; Santiago V; Silva J; Souza C; Azeredo F; Castilho M; Cilli E; Ferreira E
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681729
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a new class of HMG-CoA reductase inhibitor from Polyalthia longifolia as potential lipid lowering agent.
Sashidhara KV; Singh SP; Srivastava A; Puri A; Chhonker YS; Bhatta RS; Shah P; Siddiqi MI
Eur J Med Chem; 2011 Oct; 46(10):5206-11. PubMed ID: 21872367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
